AMENDMENT NO. 2
THIS AMENDMENT NO. 2 (this "Amendment") dated as of March 1, 2000, to
the Loan Agreement referenced below, is by and among PHARMACEUTICAL PRODUCT
DEVELOPMENT, INC., a North Carolina corporation, the subsidiaries and affiliates
identified on the signature pages hereto and FIRST UNION NATIONAL BANK. Terms
used but not otherwise defined shall have the meanings provided in the Loan
Agreement.
W I T N E S S E T H
WHEREAS, a $50 million credit facility has been established in favor of
Pharmaceutical Product Development, Inc., a North Carolina corporation (the
"Borrower"), pursuant to the terms of that Loan Agreement dated as of June 24,
1998 (as amended and modified, the "Loan Agreement") among the Borrower, the
Guarantors identified therein and First Union National Bank (the "Bank");
WHEREAS, the Borrower has requested certain modifications to Loan
Agreement;
WHEREAS, the Bank has agreed to the modifications on the terms and
conditions set forth herein;
NOW, THEREFORE, IN CONSIDERATION of the premises and other good and
valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties agree as follows:
1. In Section 6.9 of the Loan Agreement, subsections (f) and (g) are
renumbered as (h) and (i), respectively, thereof and new subsections (f) and (g)
are added thereto to read as follows:
(f) cash equity investments in and to XXxxxxxXxXxxxXxxxx.xxx,
Inc. in an aggregate principal amount (on a cost basis) not to
exceed $5,000,000 at any time;
(g) loans and advances to NeoRx Corporation in an aggregate
principal amount not to exceed $5,000,000 at any time;
2. The reference to "June 25, 1997" on the third line of the second
paragraph on page 1 of Amendment No. 1 to the Loan Agreement, which Amendment
No. 1 is dated January 30, 1999, is changed to "June 24, 1998".
3. This Amendment shall be effective upon execution of this Amendment
by the Credit Parties and the Bank.
4. Except as modified hereby, all of the terms and provisions of the
Loan Agreement (including Schedules and Exhibits) shall remain in full force and
effect.
5. The Borrower agree to pay all reasonable costs and expenses of the
Bank in connection with the preparation, execution and delivery of this
Amendment, including without limitation the reasonable fees and expenses of
Xxxxx & Xxx Xxxxx, PLLC.
6. This Amendment may be executed in any number of counterparts, each
of which when so executed and delivered shall be deemed an original and it shall
not be necessary in making proof of this Amendment to produce or account for
more than one such counterpart.
7. This Amendment shall be deemed to be a contract made under, and for
all purposes shall be construed in accordance with the laws of the State of
North Carolina.
IN WITNESS WHEREOF, each of the parties hereto has caused a counterpart
of this Amendment to be duly executed and delivered as of the date first above
written.
BORROWER: PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.,
a North Carolina corporation
By: /s/ Xxxxxxx X. Xxxxxxxx
------------------------------
Name: Xxxxxxx X. Xxxxxxxx
Title: Chief Executive Officer
GUARANTORS: PPD DEVELOPMENT, INC.,
a Texas corporation
By: /s/ Xxxxxxx X. Xxxxxxxx
------------------------------
Name: Xxxxxxx X. Xxxxxxxx
Title: Chief Executive Officer
BANK: FIRST UNION NATIONAL BANK
By: /s/ G. Xxxxxx Xxx, Xx.
------------------------------
Name: G. Xxxxxx Xxx, Xx.
Title: Sr. V.P.